Dosing starts in clinical trial of MBX 2109, PTH replacement therapy
Dosing is underway in a Phase 2 clinical trial of MBX 2109, an investigational hormone replacement therapy for people with hypoparathyroidism, according to the therapy’s developer, MBX Biosciences, with top-line expected around mid-2025. The trial, called Avail (NCT06465108), is evaluating the safety, effectiveness, and pharmacological properties…
